Method and Medicament For Inhibiting The Expression of A Given Gene
The invention relates to an isolated RNA that mediates RNA interference of an mRNA to which it corresponds and a method of mediating RNA interference of mRNA of a gene in a cell or organism using the isolated RNA.
1 . An oligoribonucleotide of double-stranded structure (dsRNA) for inhibiting the expression of a given target gene in mammalian cells, wherein the dsRNA has 15-49 base pairs comprising at least one 2′-modified nucleotide, and wherein the dsRNA has a complementary region I that is incorporated in the dsRNA.
2 . The dsRNA of claim 1 , wherein the complementary region I is 15-49 nucleotide pairs.
3 . The dsRNA of claim 1 , wherein the 2′-modified nucleotide is a 2′-methyl substituted nucleotide.
4 . The dsRNA of claim 1 , wherein the 2′-modified nucleotide is a 2′-amino substituted nucleotide.
5 . The dsRNA of claim 1 , wherein the 2′-modified nucleotide is a locked nucleotide.
6 . The dsRNA of claim 1 , wherein the at least one 2′-modified nucleotide is at the 3′ terminus of the dsRNA.
7 . The dsRNA of claim 1 , further comprising at least one thiophosphoryl group at the 3′ terminus of the dsRNA.
8 . The dsRNA of claim 7 , wherein both the at least one 2′-modified nucleotide and the at least one thiophosphoryl group are at the 3′ terminus of the dsRNA.
9 . The dsRNA of claim 1 , wherein the at least one 2′-modified nucleotide is at the 5′terminus of the dsRNA.
10 . The dsRNA of claim 1 , further comprising at least one thiophosphoryl group at the 5′terminus of the dsRNA.
11 . The dsRNA of claim 10 , wherein both the at least one 2′-modified nucleotide and the at least one thiophosphoryl group are at the 5′terminus of the dsRNA.
12 . The dsRNA of claim 1 , wherein the target gene is a mammalian gene or a viral gene.
13 . The dsRNA of claim 1 , wherein the target gene is selected from the group consisting of an oncogene, a cytokine gene, an Id protein gene, a developmental gene, a PKR gene, and a prion gene.
14 . The dsRNA of claim 1 , wherein the dsRNA is enclosed by a micellar structure.
15 . The dsRNA of claim 14 , wherein the micellar structure comprises a liposome.
16 . The dsRNA of claim 1 , wherein the target gene is expressed in eukaryotic cells.
17 . The dsRNA of claim 1 , wherein an end of the dsRNA is modified in order for the double-stranded structure to counteract degradation.
18 . The dsRNA of claim 1 , wherein the dsRNA comprises a sense strand and an antisense strand, and wherein the sense strand comprises a 2′-methyl substituted nucleotide.
19 . The dsRNA of claim 1 , wherein the dsRNA comprises a sense strand and an antisense strand, and wherein the sense strand comprises a 2′-methoxynucleotide.
20 . The dsRNA of claim 1 , wherein the dsRNA comprises a sense strand and an antisense strand, and wherein the sense strand comprises a plurality of 2′-methoxynucleotides.
21 . The dsRNA of claim 1 , wherein the dsRNA comprises two strands, one of the two strands being complementary to less than the full length of a third strand that comprises an RNA transcript, and wherein the dsRNA is capable of reducing an amount of the third strand in response to the dsRNA being introduced into the presence of the third strand in a mammalian cell, the dsRNA thereby being capable of specifically inhibiting expression of the given target gene.
22 . The dsRNA of claim 1 , wherein the dsRNA comprises a pharmaceutical composition formulated for delivery to a mammalian cell.
23 . A pharmaceutical composition comprising an oligoribonucleotide of double-stranded structure (dsRNA) for inhibiting the expression of a given target gene in mammalian cells, wherein the dsRNA has 15-49 base pairs comprising at least one 2′-modified nucleotide, and wherein the dsRNA has a complementary region I that is incorporated in the dsRNA.
24 . The pharmaceutical composition of claim 23 , further comprising a liposome enclosing the dsRNA for delivery to a mammalian cell.
25 . The pharmaceutical composition of claim 23 , further comprising at least one other different dsRNA.
26 . The pharmaceutical composition of claim 23 , wherein the 2′-modified nucleotide is a locked nucleotide.
27 . The pharmaceutical composition of claim 23 , wherein the at least one 2′-modified nucleotide is at the 3′ terminus of the dsRNA.
28 . The pharmaceutical composition of claim 23 , further comprising at least one thiophosphoryl group at the 3′ terminus of the dsRNA.
29 . The pharmaceutical composition of claim 28 , wherein both the at least one 2′-modified nucleotide and the at least one thiophosphoryl group are at the 3′ terminus of the dsRNA.
30 . The pharmaceutical composition of claim 23 , wherein the at least one 2′-modified nucleotide is at the 5′terminus of the dsRNA.
31 . The pharmaceutical composition of claim 23 , further comprising at least one thiophosphoryl group at the 5′terminus of the dsRNA.
32 . The pharmaceutical composition of claim 31 , wherein both the at least one 2′-modified nucleotide and the at least one thiophosphoryl group are at the 5′terminus of the dsRNA.